Press Releases GRI BIOPAR

Equities

GRI

US3622AW1069

Market Closed - Nasdaq Other stock markets 21:30:00 15/05/2024 BST			5-day change	1st Jan Change
0.4007 ^USD	-1.18%		-94.30%	-94.02%

04-16	GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments	MT
2023	Vallon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase	05-14	AQ
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update	05-13	AQ
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity	04-29	AQ
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar	04-25	AQ
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent	04-16	AQ
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference	04-08	AQ
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update	04-01	AQ
GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference	03-28	AQ
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators	03-14	AQ
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom	03-04	AQ
GRI Bio Announces Pricing of $5.5 Million Public Offering	02-02	AQ
VALLON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	21/04/23	AQ
Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.	21/04/23	AQ
VALLON PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	21/04/23	AQ
Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Split	20/04/23	AQ
VALLON PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	12/04/23	AQ
Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023	12/04/23	AQ
Vallon Pharmaceuticals : Merger Agreement - Form 8-K	07/04/23	PU
VALLON PHARMACEUTICALS, INC. : Other Events (form 8-K)	07/04/23	AQ
VALLON PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	04/04/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases GRI BIOPAR

Equities

GRI

US3622AW1069

Press Releases

Filters